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For the pharmaceutical industry, where the acquisition of external
knowledge is very important in knowledge creation, this study
investigated the moderating effect of the utilization of licensing, a
unilateral relationship, on the knowledge creation of R&D
co-development, a bilateral relationship. The results showed that
pharmaceutical firms that properly utilize external knowledge
through licensing contracts had larger knowledge creation
compared to firms that only utilize R&D co-development with
large organizational learning effects and risks. The study was
carried out using licensing contracts, R&D co-development, and
the data of new FDA-approved medicines targeting the top 100
global pharmaceutical companies for the past 20 years (1995 to
2015). Licensing contracts showed slightly significant moderating
effects in the correlation of R&D co-development and knowledge
creation
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Nowadays, companies in the high-tech industry not only generate
knowledge internally but also proactive receive the same from
external sources. Companies absorb knowledge of diverse
subjects from various avenues such as mergers and acquisitions
(M&As), alliances, licensing, and joint ventures (JV).
Remaining innovative by relying only on internal knowledge
creation has become very challenging, especially for the
knowledge-intensive industry. The pharmaceutical industry is a
typical example. As the terms of patents on some of the best
selling drugs that generated huge revenue in the past have
expired, active utilization of external knowledge has emerged as
the most critical factor in the innovation and growth practices of
pharmaceutical companies with regard to the development of new
medicines. The pharmaceutical industry is, arguably, the leading
industry in which markets for technology have rapidly grown and
are actively utilized (Arora and Gambardella, 2010).
According to most research findings until now, there is a greater
likelihood of the avoidance of absorption of external knowledge
as R&D productivity increases or when the production functions
become more complementary with R&D, as is the case in the
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high-tech industry. On the contrary, recent research results show
that if such a high-tech industry’s internal R&D productivity
declines, the marginal value of downstream assets that have a
close, complementary relationship with the existing R&D also
decreases. Therefore, this leads to the promotion of external
knowledge absorption (Ceccagnoli et al., 2010).
First, there is a need to clearly define licensing and joint
development because these terms have different connotations in
every industry. For instance, for some, the meaning of licensing
is limited to the extent that a licensee is allowed to produce
goods in his or her area by purchasing the patent given for mere
technologies. Further, joint development refers to autonomously
producing, and later combining, each component (for example, a
fuselage) of a product that comprises several components, rather
than jointly conducting research on a product (the Airbus case).
However, especially in an academic sense, licensing denotes an
activity where a licensor transfers technology to a licensee in
lieu of licensing fee, and joint development refers to an activity
that creates knowledge through joint R&D, not just by combining
parts (Leone et al., 2012). Furthermore, licensing has theoretical
significance because it is the most efficient means to absorb
external knowledge in terms of time and R&D costs. This is
because a licensee, apart from receiving technology, can have the
fastest and the easiest access to a licensor’s knowledge.
An R&D alliance is one of the representative external knowledge
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acquisition methods in alliances, which is the most important
element in alliance execution, and at the same time, it is the
most commonly used measure in gaining external knowledge.
Companies considering external knowledge acquisition are at the
crossroads between licensing and R&D alliance since weaknesses
could exceed strengths, as mergers and acquisitions for
knowledge acquisition could entail significant integration problems
along the process. An R&D alliance can promote exposure to and
absorption of a variety of external knowledge by companies,
ultimately helping to achieve a high level of innovative results
(Lin et al., 2012). Among various theories, such R&D alliances
can be best explained by the RBV and TC theories. The RBV
theory refers to companies seeking strategic partnerships through
an R&D alliance to share insufficient resources, and the TC
theory suggests that companies choose strategic partnerships to
minimize transaction costs. Although there are many kinds of
R&D alliances, we defined an R&D alliance as joint development
or joint R&D that constitutes the most significant constituent of
alliance execution.
R&D alliances and licensing are the most commonly executed
alliance types, especially in the knowledge-intensive industry.
According to SDC platinum, R&D alliances account for more than
70% of several alliance measures, and many research results
portray the positive relationship between R&D alliances and R&D
performance as an empirical relationship. Ahuja (2000) suggested
that R&D alliances “serve as sources of resources and
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information,” and that R&D alliance activities have a positive
relationship with a company’s patent and innovative activities.
Moreover, Baum et al. (2000) verified that the more R&D
alliances biotech venture companies have formed, the more
innovative results they have produced. As for licensing, many
research findings empirically supported that it has a positive
effect on R&D performance (Fosfuri, 2006; Leone et al., 2012).
Many studies also suggest that licensing can improve innovation
speed and, furthermore, eventually enhance companies’ absorptive
capacity as well. On the negative side, however, there are
research results that if companies depend too much on licensing,
their ability to develop new products may be impeded later on
because causal ambiguity in independent new product
development may hamper learning (Mulotte et al., 2013).
Existing studies have analyzed the large positive impact of joint
R&D development on knowledge productivity from a variety of
perspectives. However, according to a REDCap report, a wide
variety of relationships, in addition to the commonly used joint
development, are being used for external knowledge acquisition.
In particular, in recent years, the use of licensing agreements is
growing exponentially; this is because it is impractical for R&D
divisions at multinational pharmaceutical companies to conduct
research in all areas, as new drugs continue to become
increasingly segmented and specialized. In the face of the rising
number of joint R&D research projects and licensing agreements,
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existing studies show clear limitations by not reflecting this
reality. In addition, theoretically, high-tech corporations acquire
external knowledge using several methods simultaneously;
however, by analyzing the relation between one of the methods
and research productivity, existing studies demonstrate a large
gap in their assumptions. Thus, the existing studies demonstrate
the significant logical weakness of pharmaceutical companies that
overlook intermediate stage licensing by hypothesizing R&D
co-development scenarios that occur within the context of joint
knowledge creation to be 0 or 1.
My research topic originated from the following academic
interest, that is, the root of my interest can be found in the
following research question: given the reality that licensing
agreements are used in conjunction with joint R&D to acquire
external knowledge, what impact would utilizing these two
methods as separate theoretical elements have on research
productivity?
Literature Review
A great deal of research has proven the strong correlation
between joint R&D and research productivity. Several theories
exist as to why the mutual relationship joint R&D has a strong
correlation with productivity, compared with other forms of
external knowledge acquisition. The most well-known study is
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by Roathmelar et al., who state that social capital is an important
driver. Joint R&D, which is partnership-based rather than
contract-based, requires a relatively high level of trust, given the
long time period required to develop new drugs. Joint R&D
requires the exchange of technology, knowledge, and R&D
manpower over this long period of time; therefore, in the absence
of a high level of trust, it will inevitably fail. In addition,
countless examples exist where, despite a high level of effort and
the many hours spent, joint R&D relationships are terminated
because of lack of a certain level of trust, and as a result,
critical manpower and hours are wasted. Therefore, while the
achievements of successful joint R&D may be large, given the
high level of risk associated with it, a high level of trust is
required.
Other research indicates that the ongoing learning from joint
R&D is a key driver to producing positive research productivity.
Rather than being a one-way learning environment, joint R&D
allows for two-way, in-depth learning, permitting parties to learn
from each other. Therefore, a correspondingly high level of
learning is required for joint R&D success. Joint R&D that lacks
a high level of learning faces a relatively high risk of failure.
As seen above, R&D alliance has many positive effects on
innovation performance in terms of R&D productivity. However,
we also need to consider its many challenges. Information
asymmetries, opportunistic behaviors, and/or even knowledge
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leakage could occur. Many companies have tried to minimize the
side effects by narrowing the scope of either equity-based
alliances or R&D, but doing so has inherent challenges. They
have been suffering from knowledge outflow rather than inflow,
and while controlling the leakage, they have not been able to
maximize the impact of their R&D alliance. Furthermore, research
indicates that for companies with a stronger centrality of alliance
networks, business performance is more likely to be swayed by
the ratio of outflow rather than that of inflow. In other words, it
should be remembered that R&D alliances aimed at external
knowledge acquisition could boomerang on technology-led
companies and cause them serious damage. For global
pharmaceutical companies, R&D alliances could be a golden egg
laying goose but should be approached with caution (RKD thesis
citation).
In view of the above, accepting external technologies through
licensing could be a better alternative for companies to combat
information leakage. However, in the initial stage, accepting
external knowledge could give rise to strong opposition from
employees. This is called NIH (Not Invented Here) syndrome,
signifying a phenomenon of opposing external knowledge, not
created internally. A cooperative creation of knowledge through
R&D alliances could become more active if licensing can
eliminate the disagreeable sense of using external knowledge.
Nonetheless, it is true that licensing has less effect on a
company’s R&D productivity or learning than R&D alliances.
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The results from existing research ascertained that the
knowledge gained from acquisition and that from licensing
complement each other. Although the existing research did not go
any further than showing that both knowledge acquisitive
behaviors are helpful in increasing R&D productivity, the
significance of this study lies in the fact that the acquisition of
external knowledge through various methods, not just one
method, can be conducive to organizations’ innovation. This study
has substantiated that a joint adoption of the two measures does
not impede the efficiency of knowledge acquisition by other
methods. By extending the preliminary research of J. Walter, the
findings of this research proved that knowledge acquired from
alliances and licensing is complementary. This study also
provides the reasoning that problems in alliances can be solved
by undergoing a one-time licensing process.
Despite the observed facts, there were no studies that conveyed
the relationship between licensing and alliances. Recent empirical
studies that involved a context analysis of the messages from
the CEOs of those companies that are actively absorbing external
knowledge proved that among the many modes, licensing and
R&D alliances display the maximum similarity of purpose. It was
quite surprising that there had been no significant research
aiming to substantiate the relationship between these two modes,
which can be compared to the two sides of the same coin. That
provided me the starting point of my research.
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My research has maily three theoretical contributions. At first, it
is not independent, but dependent and simultaneous action.
Studies on alliances have mostly been carried out focusing either
on their formation or on execution. In particular, research on
formation has focused on what characteristics can increase the
likelihood of alliance formation with others. An underlying
assumption of the research on R&D alliance formation is that if
companies chose the policy of alliance to absorb external
knowledge, their considerations would boil down to whether they
opt for R&D alliance or not. According to actual cases and
various theses, however, companies consider R&D alliance,
licensing, and acquisition concurrently when absorbing external
knowledge. In particular, mergers and acquisitions require
extremely careful judgment because of numerous integration and
financial problems. Hence, there is no choice but to consider
licensing and R&D alliances simultaneously. However, the
research so far has addressed these two measures in parallel
aspects. In reality, companies do not exclusively choose only one
of these measures. Most companies adequately and
simultaneously utilize both measures. Therefore, existing studies
that postulate that companies can use either of the two measures
independently to acquire external knowledge represent inadequate
research.
As such, licensing and R&D alliances are among the primary
methods in gaining access to external knowledge. Nonetheless,
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the studies so far have focused on the respective factors that
determine each behavior. That is, they saw them as a two
independent behaviors. However, companies’ external knowledge
acquisition behaviors do not consider licensing and R&D alliances
to be mutually exclusive. By establishing that the knowledge
gained from licensing and the knowledge acquired from M&As
are complementary, Ceccagnoli et al. (2008) proved wrong the
preconception that utilizing various methods to acquire external
knowledge may hamper R&D productivity. Further, Yang et al.
(2011) confirmed that alliance partners are more likely to become
a target for M&As, and that acquiring one’s existing alliance
partner is more effective than acquiring a completely new
acquisition target. While independent studies on acquisition and
alliances have been integrated, it is quite surprising that there
has been no research revealing the relationship between licensing
and alliances. The significance of this research lies in its conduct
of an empirical analysis of the relationship between the two
representative behaviors of companies’ external knowledge
acquisition.
Second, it contributes in that indirect experience, not direct
experience, can bring about a positive effect. There have been
many research results so far that highlight the positive effect of
experiences on R&D alliances, thereby reflecting a positive
influence on R&D performance. However, this thesis has
significance in that the first step has been initiated toward
clarifying the hitherto independent relationship between licensing
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and R&D alliances by demonstrating that licensing, not R&D
alliance experience, can indirectly have a positive influence on
R&D performance.
Finally, it contributes in that minimizing the negative effects of
R&D alliances. Although many research findings have highlighted
only the positive effects (knowledge acquisition) of R&D
alliances, recent research results show that there are as many
negative effects as positive ones. However, measures to minimize
such negative effects have not been specifically addressed. By
showing that the negative effects of R&D alliances can be offset
if collaboration in the form of licensing is utilized, this thesis has
a meaningful contribution in that it can provide managerial
implications beyond a theoretical paper.
Based on this rationale, research has been conducted to establish
the relationship between strategic alliances and acquisition, which
are, in effect, the most widely used in companies’ expansion
strategies. A recent research indicates that alliance partners have
a higher probability of becoming the target for M&As, and that
if the partners who had a strategic alliance experience were
merged and acquired, the M&As had a greater likelihood of being
successful. In other words, strategic alliances and M&As are not
independent options, rather they can be simultaneously utilized by
companies at any time. Further, other research showed that
companies’ utilization of various methods lead to increase in
knowledge production by proving that licensing and M&A would
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serve as mutual substitutes or become complementary to each
other with regard to knowledge absorption.
Theory and Hypothesis
Social capital theory
R&D alliances are characterized by many problems; hence,
without a high level of trust, they could rather bring forth side
effects. Therefore, trust building should come first through
licensing, a lower level of knowledge acquisition; following this,
R&D alliances, a higher level, should be sought. Progression in
that order presents a higher probability of success.
Social capital theory suggests that the amount of knowledge that
two companies can acquire differs based on their social capital
with respective partners. Social capital can be largely comprised
of social interaction, relationship quality, and partner network ties.
Among others, social interaction symbolizes the depth of an
information relationship between two organizations (Larson, 1992;
Nahapiet & Ghoshal, 1998; Fey & Birkinshaw, 2005). Relationship
quality represents a theory that the trust and reciprocity between
two organizations determines the ambience and intensity of their
amicable relationship (Dyer & Singh, 1998; Ring & Van de Ven,
1992; Fey & Birkinshaw, 2005).
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Both the inflow and outflow of knowledge occur frequently in a
partnering-based (not contract-based) relationship like R&D
alliances. As the purpose of these relationships is knowledge
creation and sharing of expertise, higher level of achievements
are possible because companies can comprehend not only their
counterparts’ technologies but also their underlying tacit
knowledge and cultures. The extent of knowledge that can be
absorbed depends on each company’s absorptive capacity and the
passion with which companies collaborate with each other, and
more (Cohen & Levinthal, 1990; Hamel, 1991; Inkpen, 1992; Lane
& Lubatkin, 1998; Fey & Birkinshaw, 2005). Since R&D alliances
are not a zero-sum game, in which one side’s gain of knowledge
is balanced by the other side’s corresponding deficiency, they
have a win-win structure that can generate a higher level of
knowledge acquisition if a stronger level of trust and knowledge
is established (Fey & Birkinshaw, 2005). As such, companies that
want to acquire external knowledge through R&D alliances need
a much higher level of trust relationship and understanding of
counterpart companies, compared with the case where they
acquire external knowledge through licensing, that is, a
contract-based action.
Repeated interaction can have a greater impact on relationship
formation and trust building, and its influence is stronger when
in partnership than in contracting. There are various reasons as
to why a higher level of knowledge acquisition occurs in a
partnering relationship, where a stronger trust is built, rather
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than in a contracting one (Rothaermel et al., 2009). Rothaermel et
al. (2009) reasoned that a higher level of knowledge acquisition
occurs since a higher level of trust relationship can provide an
opportunity to organizations to access the networks of their
counterpart companies.
The occurrence of these problems can be explained by social
capital theory. Network relations may enhance the social capital
of a company by making it easier to access information, technical
expertise, and financial support. However, these relationships may
simultaneously lead to social liability (by reducing the
possibilities to relate to companies outside the network, risk of
spillover, and high coordination costs of network relations). In
general, R&D relationships are not very tightly knit; hence,
leading to problems relating to lack of information and
opportunism.
Organizational learning theory
Companies, as the main agents of behavior with “bounded
rationality,” act based on their experience and accumulated
knowledge (Levinthal & March, 1993; Yang et al., 2011). Many
studies on M&As have proved that companies’ decisions on
M&As are dependent upon the accumulated knowledge from their
experiences (Haleblian, Kim, & Rajagopalan, 2006; Hitt, Harrison,
& Ireland, 2001; Levinthal & March, 1993; Vermeulen & Barkema,
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2001; Zollo & Reuer, 2010; Yang et al., 2011). Although many
studies have discussed the influence of alliances and M&As on
companies’ experiences, decision making, and ultimately on their
business performance, there was little research on the impact that
the experience and knowledge accumulated from two different
fields might have on other fields.
In reality, however, there is a high propensity that many
organizations would take over companies with whom they have
established relations through their existing alliance, rather than
the companies they do not know at all. In other words, the
experiences from alliances and the resulting network relationships
have an inevitable influence on the decision making concerning
M&A (Lin et al., 2009; Yang et al., 2011). Nonetheless, regarding
companies’ M&A decision making and related outcomes, the
existing academic studies are characterized by a major logical
flaw of viewing the behaviors two different companies in
complete isolation and observing them in a mutually exclusive
scenario.
By employing the behavioral learning theory, Yang et al. (2011)
proved that experience gained from alliances and a firm’s relative
network position wield a significant impact on M&A decision
making in future and elicit better outcomes. Yang et al. (2011)
were able to persuasively explain about some companies’
acquisition decisions and post-acquisition performance, which had
been explained using financial theories earlier, by integrating the
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individual factors related to alliance, acquisition, and learning
research.
Yang et al. observed that companies that formed a relationship
through alliance would be more aware of important information
with which they could precisely evaluate counterpart companies.
This would exert a more positive influence on their M&A
decision making. This is because with regard to the M&As of
high-tech companies, determining the intrinsic hidden worth of
companies is far more important than calculating the value,
which can be financially determined (Dussauge, Garrette, &
Mitchell, 2000). Several studies have already explained the link
between M&A and favorable outcome because M&A of
companies that were alliance partners may provide better
information and, consequently, reduce uncertainty in seeking,
evaluating, and even consolidating M&A targets (Porrini, 2004;
Yang et al., 2011).
A very limited number of studies have shown that experiences
from companies’ different fields can spread to, and eventually
exert a positive effect on other fields. Until now, there have been
only a few studies focusing on the methods through which
accumulated experience and knowledge can spread and the
influence they have (Zollo & Reuer, 2010; Yang et al., 2011). This
study has significance in that this is the first study that linked
licensing and R&D alliance among other activities of companies.
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Technology acquisition through collaboration is essential in the
high-tech industry. However, it is certainly the most complex
and risky activity among lots of alliance types that two firms
that have completely different knowledge characteristics jointly
create new knowledge through cooperative research development.
As mentioned above, R&D alliances are fraught with risks.
Research and development does not go as smoothly as expected
due to opportunistic behaviors and a limited understanding of
each other’s technologies, and there are numerous difficulties in
absorbing newly created knowledge. These reasons explain why
many firms that had not been familiar with external technology
acquisition imprudently tried to acquire technologies through R&D
alliance from the beginning but met with repeated failures.
Several studies suggest that the experience effect or knowledge
spillover caused by licensing was less detrimental (Fey &
Birkinshaw, 2005; Yang et al., 2011). Licensing is undoubtedly an
effective method for external technology acquisition, but effects of
knowledge acquisition will be insignificant in the long run since
licensing reflects a unilateral acceptance of existing technologies.
It remains a fact, however, that licensing has fewer side effects.
In this regard, for the companies that aggressively acquire
external technologies, licensing will be useful as a middle step
before concluding an R&D alliance.
Hypothesis 1. There is a positive relationship between




Absorptive capacity is generally developed through continuous
funding of, and engaging in, R&D over time (Cohen and
Levinthal, 1990; Rothaermel and Alexandre, 2009).
“It requires a substantial research capability to understand,
interpret, and to appraise knowledge that has been placed upon
the shelf - whether basic or applied. The cost of maintaining
this capability [in terms of R&D dollars] is high” (Rosenberg,
1990; Rothaermel and Alexandre, 2009).
Absorptive capacity includes a capability to search and evaluate
existing technologies in the market and to appraise their exact
value, as well as to properly absorb technologies as one’s own
(Mowery, 1983; Cohen and Levinthal, 1990; Helfat, 1994;
Rothaermel and Alexandre, 2009). Therefore, absorptive capacity
enables companies to correctly appraise the value of external
knowledge and to selectively absorb the knowledge useful for
them, and in the end, it can be highly conducive to a firm’s
knowledge acquisition (Arora and Gambardella, 1994; Rothaermel
and Alexandre, 2009). As such, absorptive capacity can be
divided into two components: the ability to adequately search and
evaluate technology outside of a company and the ability to
effectively accumulate and utilize it. If emphasis is placed only on
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one of these abilities, a firm may face serious challenges in
conducting knowledge acquisition activities.
Rothaermel and Alexandre (2009) suggested that there are two
separate abilities in terms of a firm’s knowledge acquisition
behavior: the ability to adequately search for, evaluate, and
acquire external knowledge and the ability to internally generate
knowledge on its own. They also pointed out the balance and
ambidexterity between these two abilities.
When a firm possesses an adequate level of absorptive capacity,
it tends to not only be more sensitive to opportunities that
present themselves in their technological environments, but also
be more proactive in exploiting those opportunities by combining
internal and external sources of knowledge (Cohen and Levinthal
1990; Rothaermel and Alexandre, 2009).
In the pharmaceutical industry, it is quite important for global
pharmaceutical companies to be able to continuously search for
information about a wide variety of new drug candidate
substances that are developed by small scale biotech firms all
over the world. It is equally critical for them to explore the
chemical components that can be beneficial to research and
development. If they identify appropriate technologies, they can
absorb external knowledge through licensing.
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Absorptive capacity in searching and applying external knowledge
can be enhanced through licensing. Consequently, outcomes from
R&D alliance, in which knowledge is jointly developed, can be
eventually maximized.
According to a research result, accepting licensing and acquisition
at the same time has a mutually complementary effect in
research productivity. Although there are many studies
concerning the positive influence each of these two actions has
on research productivity, in reality, companies perform not just
one action, but two actions simultaneously. There are limitations
associated with the existing studies that analyzed the effects of a
single action only. According to empirical research findings,
accepting external knowledge by using the two measures
simultaneously results in further enhancing the research
productivity created by one measure. Furthermore, the positive
effect of licensing can get more pronounced when the companies
that accept knowledge possess more scientific technologies (that
is, when they have knowledge with strong basic technologies).
We believe that the complementary effects of research
productivity can be much bigger if R&D alliance, rather than the
acquisition that has integration problems, is utilized in lieu of
licensing. We interpret this finding as suggesting that licensing
leads to spillovers and learning while avoiding integration
problems. Therefore, licensing benefits from the scientific
capabilities of the buyer since they typically enhance absorptive
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capacity and facilitate knowledge flows. R&D alliance has a
higher correlation than licensing with respect to R&D
performance. Hence, the companies that have gone through the
middle phase called licensing, without directly opting for a joint
R&D formation, have a higher probability of pursuing alliance
formation with each other.
Hypothesis 2. The level of using licensing moderated
the positive relationship between the level of using
R&D co-development and knowledge creation.
Data & Method
Sample
I used joint Venture & alliance data in SDC Platinium as R&D
co-developmen and licensing data. SDC Platinum is one of the
representative database in the field of M&A and alliance, which
draws all kinds of data from formal public news to informal
information only flew in Bloomberg terminal. I select global top
100 pharmaceteutical campanies in terms of sales in 2012 as
sample data. It is relatively small size of data sample enough to
conduct reliable regression analysis. But, pharmaceteutical
industry has been operated by almost top 100 global companies
and others are mostly local companies which do not have their
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own research capability, but only import drugs or make generic
drug using expired patent. Also, they were not captured global
database such as SDC platinum because they play mostly in
their country, or even their regional district. This fact that my
research has relatively small size sample data is one of the most
challenging and weakest point in this research. I used simple
regression analysis. I encountered some empirical problems in
that under 50 firms showed very low number of r&d
co-development or licensing behavior, which are mostly 0 or at
most 3 Sampson(2007) used negative binominal analysis to solve
this kind of empirical problems . The other difficulty which I
encountered conducting empirical analysis is that some samples
which showed 0 or 1 in terms of R&D codelopmentor licensing
showed hundreds of transaction in terms of FDA approval. It
might be due to that SDC platinum didn’t collect proper data. So,
I extracted 24 sample to conduct a reasonable empirical analysis,
which concluded total number of 76 data sample.
SDC Platinum’s Joint Venture & Alliance database was used to
collect R&D co-development and licensing data. SDC Platinum is
the most representative alliance-related database, which not only
captures not only a variety of officially announced merger and
acquisition (M&A) and alliance data, but also unofficial
announcements shared in the news or via the Bloomberg
terminals. The sample was selected to include the top 100
pharmaceutical companies based on 2012 sales. The sample size
was slightly small for credible regression analysis; however, the
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pharmaceutical industry is concentrated largely in the top 100
companies, and companies further down in rank are mostly local
companies rather than global ones. Many of these are not even
identified in the SDC Platinum database, and the few that are
identified do not have a sufficient number of R&D
co-development or licensing agreements to produce a meaningful
sample to conduct regression analysis. This posed the biggest
challenge, as well as limitation, for this study’s empirical
analysis. The study used a simple regression model as its
statistical methodology. The biggest challenge faced using the
simple linear regression was that companies in the bottom 50
increasingly had very simple recorded incidences of R&D
co-development or licensing agreements, such as 0 or 1.
Sampson (2007) used a negative binominal model to overcome
such challenges. This research, however, used simple linear
regression. Some of the companies with 0 or 1 R&D
co-development or licensing samples still had hundreds of FDA
approvals; this was likely due to the fact that the SDC Platinum
database did not have accurate data. Therefore, I used a general
regression analysis excluding 24 samples, which were inconsistent
among the 100 samples.
Independent variable
Among the numerous alliance data, only R&D co-development
and licensing data were extracted, and cross licensing, which is
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generally used to avoid patent lawsuits rather than for general
external knowledge acquisition, were excluded from the sample.
Most pharmaceutical companies showed patterns of using R&D
co-development as the standard, and using licensing as ancillary
for external knowledge acquisition. In reality, however, companies
do not specify the two in external communications or in the
news; therefore most of the data show the two methods as being
used together. This is why, despite selecting a time span of 20
years, pure R&D co-development and licensing samples barely
exceed a few hundred, and the top 100 companies by sales
provided samples less than several dozen. Thus, presenting
challenges in conducting credible empirical analysis.
I extracted cross licensing data because firms generally use cross
licensing contract to avoid patent litigations. Most of
pharmaceteutical firms mainly use R&D co-deveopment and use
licensing contract as supplemental method for the purpose of
acquiring external knowledge. But practically many firms didn’t
give accurate information to public between R&D co-development
and licensing in the past times. Generally, they just use the trem
“R&D alliance”. Even though they give accurate information,
news company or database company did not discern between
these two methods in the past time. It is because that licensing
was not used broadly and it was not that recognized as a
independent method to acquire external knowledge. So although
we collected dataset for 20 years, we did not collect enough data
sample. Most company which ranked under 50 recorded at most
- 28 -
0 or 1 in terms of licensing deals. It is very challenging when I
conducted empirical analysis, but I could not solve this problem.
Dependent variable
The dependent variable was the number of FDA approvals of the
top 100 pharmaceutical companies. FDA approval could be
confirmed through the FDA’s Orange Book list. The Orange
Book list catalogs FDA-approved new drugs, and the recent
change to hosting the Orange Book data online allows the data
to be collected more readily. Existing research sometimes uses a
R&D alliance’s output, such as number of patents, as the
dependent variable, but since FDA approvals and whether a
product can be released are more meaningful than the number of
patents, the number of FDA approvals was used as the
dependent variable. Furthermore, because the Orange Book
requires the patents for all listed new drugs that earned FDA
approvals to be listed in the same way, using the number of
FDA approvals as the sole dependent variable was determined as
a way to avoid any theoretical weakness.
I used the number of FDA approval which global top 100
pharmaceutical have obtained as dependent variable. I could check
out the number of FDA approval on website of FDA, which so
called “Orange book”. Organge book was originally orange color
covered book which FDA listed all drugs that FDA had
approved. They recently uploaded all the dataset on website, so
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we can collect data just logging in. Some prior research used the
number of patent as dependent variable. But specifically in
pharmaceutical industy, the importance of FDA approval is much
stronger than the importance of getting patent because new
drugs consist of many related patents. It does mean that just
patent itself doesn’t work at all. Also FDA policy require all
pharma firms to upload related patents when they apply new
drugs approval. These facts made me think using FDA approval
as a dependent variable is proper and has not any logical
problems.
Control variable
It is assumed that research and development activities of a
pharmaceutical firm take place over a long period of time. In
addition, such firms are capable of investing significantly large
amounts on R&D, consequently exhibiting high organizational
learning ability and high absorptive capacity. Accordingly, these
companies will not be able to accurately measure the positive
effects of licensing on R&D co-development. Hence, in this
context, the age and size of each pharmaceutical firm were
chosen as the control variables. While there may be suggestions
that aside from these control variables, the number of patents
and number of FDA approvals should rightfully be considered as
control variables, the process of data collection revealed that once
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the size and age of the firm are controlled, the other control
variables are almost insignificant in their influence. Meanwhile,
the age of the firm was measured by the date of establishment
as posted on the website of each firm, or if any of the firms
were acquired, the age of the company was measured from the
date of acquisition. While the data for measuring size may vary,









As shown in Table 1, there is a correlation between R&D
co-development and FDA approvals with licensing as a
moderator. The firm size, a control variable, demonstrated a
strong correlation with FDA approvals as well. R&D
co-development, a dependent variable, did not exhibit a strong
correlation with FDA approvals. Licensing, a moderator variable,
showed a relatively strong correlation with the independent
variable FDA approvals. To sum up, the moderator variable
(licensing), the control variables (age and size of the
pharmaceutical firms), the independent variable (R&D
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co-development), and the dependent variable (FDA approvals)
showed highly significant correlations.
As shown in Figure 1, it was found that licensing, which was
measured as a moderator, had a significant moderating effect
between R&D co-development and FDA approvals, which was
the knowledge generation variable
Conclusion
This study explored the effects of external knowledge acquisition
—specifically, in the pharmaceutical industry—where the ability to
generate knowledge through R&D is crucial for sustainable and
optimal financial performance. In contrast with the past where
internal knowledge generation was the norm, the current industry
practice is to collaborate with an external partner to broaden the
parameters of acquired external knowledge and maximize its
impact.
In particular, R&D co-development is currently the most common
form of this collaboration, where the two parties jointly develop
new medicine. However, R&D co-development is largely about
two firms—with most of the time very different organizational
and research cultures—collaborating over time to create products
and this can have negative performance and production
implications. For instance, such partnership may result in
- 32 -
opportunistic behavior, lack of commitment, and even lack of
trust—because of the fear of knowledge leakage—prompting one
party not to fully disclose the knowledge they possess. For
instance, R&D co-development which aimed to produce maximum
results at half the cost were most often inefficient and frequently
ended with both partners filing lawsuits against each other over
issues of technology leak or patent ownership.
In contrast, licensing contracts whereby one party provides
information to the other are free from such issues. It can be
argued that from the perspective of organizational learning, the
effects are weaker than R&D co-development, where effects are
more innovative; however, this does not make joint learning the
best course of action. In this regard, it was hypothesized that the
appropriate utilization of licensing by firms will result in better
performance in terms of knowledge creation, compared to firms
that only utilize R&D co-development in obtaining external
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외부지식습득이 지식창출에 있어서 매우 중요한 제약산업에 있어서
일방적인 관계인 라이센싱 계약의 적절한 이용이 쌍방적인 관계인
공동연구개발이 지식창출에 얼마나 조절효과를 미치는지
연구해보았다. 연구결과, 조직학습 효과는 높지만 그만큼 위험성도
큰 공동연구개발만을 활용하는 제약회사보다 상황에 따라 적절히
라이센싱 계약을 통하여 외부지식 습득을 활용하는 제약회사가 더
큰 지식창출을 해 내는 것으로 밝혀졌다. 세계　 １００대
제약회사가 1995-2015년까지 20년 동안 맺은 라이센싱계약과
공동연구개발 그리고 FDA에서 허가받은 신약 데이터를 기초로
연구를 수행하였으며 라이센싱 계약은 공동연구개발이 지식창출에
미치는 상관관계에 있어서 미약하게나마 유의미한 조절효과를
보여주었다.
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